 REDWOOD CITY, Calif., Nov. 03, 2020 GLOBE NEWSWIRE -- Soleno Therapeutics, Inc. Soleno NASDAQ: SLNO, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentation of body composition data from the Companys Phase III trial, DESTINY PWS C601, evaluating once-daily Diazoxide Choline Controlled Release DCCR tablets for patients with Prader-Willi Syndrome PWS. The results were presented today by Parisa Salehi, M.D., Clinical Director of the Prader-Willi Syndrome Clinic at Seattle Childrens Hospital, in a late-breaking oral presentation at The Obesity Societys ObesityWeek 2020 meeting. Dr. Salehi presented the data on behalf of the DESTINY PWS Investigators. 